Global Ultrafast Laser Technology Industry Research 2024-2034: Biomedical Applications Boost Demand, Quantum Technologies Present Lucrative Opportunities
June 19, 2024 09:11 ET
|
Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Ultrafast Laser Technology Market - A Global and Regional Analysis: Focus on Application, End-use Industry, Type, Pulse Duration, and Region - Analysis...
Kriya Appoints Katherine Eade as Chief Legal Officer
June 18, 2024 09:05 ET
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
June 18, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K....
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia
June 18, 2024 07:30 ET
|
Vyluma, Inc.
Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children.
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
June 18, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
June 18, 2024 06:27 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA...
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
June 17, 2024 15:43 ET
|
Spherix Global Insights
EXTON, PA, June 17, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
June 14, 2024 03:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
June 13, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of...
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
June 13, 2024 11:39 ET
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...